Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

An improved long-term sales target today revitalised GSK shares after their dismal 2024. The confidence in GSK’s drugs ...

As discussions continue, the people added that GSK (NYSE:GSK) and IDRx could opt out of the deal, or the company will attract a new buyer. A clinical-stage biotech founded in 2022, IDRx has ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The company noted that the new presentation has the same composition as the reconstituted vaccine. The submission is based on data demonstrating comparability between the two. GSK's shingles ...